Nouscom, a clinical-stage biotechnology company focused on cancer interception, announced on October 19, 2026 the closing of an oversubscribed Series D financing round totaling €120 million, equivalent to US$135 million. The round was co-led by M Ventures and Revelation Partners, with new investors including Angelini Industries, the European Investment Bank, and Neva SGR. All existing international life sciences investors also participated, reflecting strong confidence in the company's clinical pipeline and recently published data.
Oversubscribed Financing and Investor Syndicate
The new investment includes commitments from Angelini Industries through Angelini Investments, the European Investment Bank through its Aurea co-investment facility with Angelini Ventures, and Neva SGR, part of the Intesa Sanpaolo Group. Existing backers such as 5AM Ventures, Andera Partners, Bpifrance, CDP Venture Capital, and EQT Life Sciences also took part in the round. The oversubscribed demand highlights investor conviction in Nouscom's off-the-shelf neoantigen approach and its potential to address significant unmet medical needs.
Advancing NOUS-209 in Lynch Syndrome
Proceeds from the Series D financing will fund the advancement of NOUS-209, an investigational off-the-shelf neoantigen-based cancer immunotherapy, through a single global registration-enabling clinical trial for cancer interception in Lynch Syndrome carriers. The U.S. Food and Drug Administration has granted Fast Track designation to the program, recognizing its potential to address a serious condition. This trial represents a critical step toward offering Lynch Syndrome carriers an option beyond surveillance and elective surgery.
Long-Term Clinical Data Presented at ESMO
The financing announcement coincides with the presentation of long-term cancer interception data from a Phase 1b/2 trial of NOUS-209 at the European Society of Medical Oncology Congress in Madrid, Spain, from October 23 to 27, 2026. The abstract reports that all evaluable Lynch Syndrome carriers dosed with NOUS-209 remained free of advanced adenomas and colorectal cancer after years 1 and 2. Evaluable patient counts were 43 at year 1 and 17 at year 2.
These results represent an encouraging signal of durable clinical activity consistent with a treatment effect relative to the expected incidence in Lynch Syndrome carriers. The clinical findings were strengthened by broad, potent, and durable anti-neoantigen T-cell responses driven by NOUS-209, and the immune responses were further enhanced following annual re-treatment. The trial's principal investigator, Eduardo Vilar-Sanchez, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center, presented the findings.
Investor and Leadership Commentary
Nouscom Chief Executive Officer Marina Udier, Ph.D., said the company was built to change the equation for more than two million Lynch Syndrome carriers who face up to an 80% lifetime cancer risk and currently have only surveillance and surgery as options. She noted that the financing and ESMO data bring the company closer to stopping cancer before it starts. Göran Ando, M.D., Independent Chair of the Board, welcomed the new investors and said the backing accelerates NOUS-209's clinical development.
Scientific Rationale and Disease Context
NOUS-209 targets tumors with mismatch repair deficiency and microsatellite instability by delivering 209 shared frameshift peptide neoantigens using two proprietary viral vectors. This approach trains the immune system to recognize and attack cancerous and precancerous cells before tumors can develop. Lynch Syndrome is a common inherited condition that substantially raises lifetime risks for colorectal, endometrial, and urothelial cancers.
With €120 million in new capital and long-term clinical data presented at a major oncology congress, Nouscom is positioned to advance a registration-enabling trial that could redefine care for Lynch Syndrome carriers. The company's off-the-shelf neoantigen platform offers a potential shift from surveillance and surgery to active cancer interception. If successful, NOUS-209 may provide a new standard for preventing cancer in a population with limited options and high lifetime risk.